Pricing and availability is not currently available.

biological source

human lung

growth mode

Aggregates in suspension


Not specified


Not specified


Not specified


Not specified


cell culture | mammalian: suitable

relevant disease(s)


shipped in

dry ice

storage temp.


Related Categories

Cell Line Origin

Human small cell lung cancer, drug-resistant

Cell Line Description

NCI-H69/CPR is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.


Drug-resistance studies, small cell lung cancer

Culture Medium

RPMI 1640 + 2mM Glutamine + 0.4μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).

Subculture Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37ºC; resuscitate in drug-free medium until first passage.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.


NONH for all modes of transport

Certificate of Analysis
Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.